{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-022421","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2023-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.798928+00:00","generated_at":"2026-06-13T22:29:05.431331+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Aadi Bioscience annual meeting elects directors, says-on-pay passes, auditor ratified","bullets":["Elected three Class III directors: Aghazadeh (8.36M for), Maroun (9.87M), Reeve (9.87M).","Advisory say-on-pay approved: 9.74M for, 0.28M against, 17K abstentions.","Shareholders voted for annual say-on-pay frequency (9.83M for 1 year); next vote by 2029.","Ratified BDO USA as auditor for FY2023: 13.85M for, 73K against, 3K abstentions."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-022421","json":"https://secwatch.observer/filing/0001628280-23-022421.json","markdown":"https://secwatch.observer/filing/0001628280-23-022421.md","text":"https://secwatch.observer/filing/0001628280-23-022421.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000162828023022421/0001628280-23-022421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000162828023022421/aadi-20230614.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T22:29:05.431331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"135e28a41469c0ad9c678e8813bc57cad291eae2","claim":"Whitehawk Therapeutics, Inc. shareholders approved Ratification of the appointment of BDO USA LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-14 meeting.","evidence_excerpt":"For Against Abstentions 13,850,448 72,970 2,786","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000162828023022421/0001628280-23-022421-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"},{"claim_id":"5df463624a3165c78aeaee79e9a761bf8c234720","claim":"Whitehawk Therapeutics, Inc. shareholders approved To approve, on an advisory (non-binding) basis, the frequency of future Say-on-Pay Votes. at the 2023-06-14 meeting.","evidence_excerpt":"1 Year 2 Years 3 Years Abstentions Broker Non-Votes 9,832,520 2,546 75,231 120,267 N/A","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000162828023022421/0001628280-23-022421-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"},{"claim_id":"c23803fa1bfa1f905fabbe192829377b7f509d76","claim":"Whitehawk Therapeutics, Inc. shareholders approved To approve, on an advisory basis, the compensation of the named executive officers identified in the 2022 Summary Compensation Table in the “Executive Compensation” section of the Proxy Statement. at the 2023-06-14 meeting.","evidence_excerpt":"For Against Abstentions Broker Non-Votes 9,738,074 275,337 17,153 3,895,640","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000162828023022421/0001628280-23-022421-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"},{"claim_id":"cf26080367b2b62857b1b0092422bb5b592a3c86","claim":"Whitehawk Therapeutics, Inc. shareholders approved Election of three Class III directors to serve until the 2026 Annual Meeting of Stockholders and until their respective successors have been elected or qualified. at the 2023-06-14 meeting.","evidence_excerpt":"Broker Director For Withheld Non-Votes Behzad Aghazadeh, Ph.D. 8,361,137 1,669,427 3,895,640 Richard Maroun 9,872,401 158,163 3,895,640 Emma Reeve 9,871,998 158,566 3,895,640","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000162828023022421/0001628280-23-022421-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}